Cover Image

乾燥粉末吸入器 (DPI) :產品,治療,企業,預測

Dry Powder Inhalers: Products, Therapeutics, Players and Forecasts

出版商 Greystone Research Associates 商品編碼 228361
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
乾燥粉末吸入器 (DPI) :產品,治療,企業,預測 Dry Powder Inhalers: Products, Therapeutics, Players and Forecasts
出版日期: 2017年05月02日 內容資訊: 英文

本報告提供全球乾燥粉末 (乾粉) 吸入器 (DPI) 市場相關調查分析,概要,需求推動因素,市場規模與市場佔有率,設計的必需要素,技術,市場發展上的問題等系統性資訊。



  • 設備與處方
  • 市場區隔與適應症
  • 競爭技術
  • 現有治療目標
  • 人口統計和成長率
  • 推動市場要素
  • 風險要素


  • 乾燥粉末處方
  • 粒子技術/工程
  • 乾燥粉末加工
  • 乾燥粉末包裝
  • DPI產品市場區隔
  • DPI吸入器設計類別
  • 貯存設備
  • 個別給藥設備
  • 專利技術設備
  • DPI設備的可用性
  • 客戶固有的DPI設備
  • 多重客戶端的DPI設備
  • 開發階段的設備



  • 單一藥物
  • 雙藥物


  • 單一藥物
  • 雙藥物


  • 上呼吸道
  • 氣喘
  • COPD
  • 支氣管痙攣
  • 全身性症狀
  • 遺傳性疾病
  • 感染疾病
  • 代謝性疾病
  • 神經學
  • 其他全身性症狀市場


  • 法規上的問題
  • 設備的品牌
  • 患者配合度與易用性
  • 醫療保健的經濟



Product Code: DPJ444K17

Converging Factors Driving the Growth of Dry Powder Inhaled Delivery

The Dry Powder Inhalers Market Report examines the rising potential of dry powder inhalation. This market is being driven by research activity in powder formulations, advances in particle engineering, and the development of novel device architectures. The combination of improved particle properties and more efficient inhaler designs is creating new opportunities for dry powder inhalation and expanding the range of active compounds that can be effectively delivered to the lung via DPI. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient - friendly and cost -effective. Our analysis contained in the dry powder inhalers market report illustrates that inhaled administration in general, and DPI in particular, are well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and the commercialization of therapeutic drugs.

What You Will Learn

  • What inhalable drugs are supplied in powder form, how are they marketed, what are the device specifics, and who markets them?
  • What inhalable dry powder drugs are in late stage development, who are the developers, and what indications are they targeting?
  • What are the major factors driving inhaled dry powder drug/device demand?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2024?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, technologies and market development issues for dry powder inhalation products?
  • What are the significant economic, technology, and regulatory factors affecting the market for dry powder inhalers?

Table of Contents

Executive Summary

Inhaled Drug Therapeutics

  • Devices and Formulations
  • Market Segments and Indications
  • Competing Technologies
  • Established Therapeutic Targets
  • Demographics and Growth
  • Market Drivers
  • Risk Factors

Dry Powder Technology & Markets

  • Dry Powder Formulations
  • Particle Technology/Engineering
  • Dry Powder Processing
  • Dry Powder Packaging
  • DPI Product Segments
  • DPI Inhaler Design Categories
  • Reservoir Devices
  • Discrete Dose Devices
  • Proprietary Technology Devices
  • DPI Device Availability
  • Customer-specific DPI Devices
  • Multi-client DPI Devices
  • Development-stage Devices

DPI Product Assessment & Analysis

FDA Approved DPI Products

  • Mono-drug Products
  • Aclidinium
  • Albuterol
  • Budesonide
  • Fluticasone
  • Formoterol
  • Glycopyrronium
  • Indacaterol
  • Insulin
  • Loxapine
  • Mometasone
  • Salmeterol
  • Tiotropium
  • Tobramycin
  • Umeclidinium
  • Zanamivir
  • Dual Drug Products
  • Fluticasone+Salmeterol
  • Fluticasone+Vilanterol
  • Glycopyrronium+Indacaterol
  • Umeclidium+Vilanterol

EMA Approved DPI Products

  • Mono-drug Products
  • Aclidinium
  • Glycopyrronium
  • Indacaterol
  • Umeclidinium
  • Dual Drug Products
  • Aclidinium+Formoterol
  • Budesonide+Formoterol
  • Fluticasone+Salmeterol
  • Fluticasone+Vilanterol
  • Glycopyrronium+Indacaterol
  • Umeclidinium+Vianterol

Therapeutic Segment Analysis, Data & Forecasts

  • Upper Respiratory
  • Asthma
  • COPD
  • Bronchospasm
  • Systemic Indications
  • Hereditary Disease
  • Infectious Diseases
  • Metabolic Conditions
  • Neurology
  • Other Systemic Markets

Market Factors

  • Regulatory Issues
  • Device Branding
  • Patient Compliance and Ease of Use
  • Healthcare Economics

Company Profiles

Back to Top